Skip to main contentSkip to navigation
Ovarian Cancer Research Alliance
Research Exchange
Donate

Investigator

Zhikun Shi

Second Affiliated Hospital Of Jilin University

Research Interests

ZSZhikun Shi
Papers(1)
AKT1 participates in …
Institutions(1)
Second Affiliated Hos…

Papers

AKT1 participates in ferroptosis vulnerability by driving autophagic degradation of FTH1 in cisplatin-resistant ovarian cancer

Resistance to cisplatin (DDP)-based chemotherapy is an important reason for the failure of ovarian cancer treatment. However, tumor cells resistant to chemotherapy may expose vulnerability to other cell death pathways. Here, we found that DDP-resistant ovarian cancer cells are more susceptible to erastin-induced ferroptosis. It should be noted that this vulnerability does not depend on the weakening of classical ferroptosis defense proteins, but is caused by the reduction of ferritin heavy chain (FTH1). DDP-resistant ovarian cancer cells maintain a high level of autophagy to escape the pressure of chemotherapy, which ultimately leads to increased autophagic degradation of FTH1. We further revealed that the loss of AKT1 was the reason for the increased autophagy level of DDP-resistant ovarian cancer cells. Our study provides new insights into reversing DDP resistance in ovarian cancer by targeting ferroptosis pathway, and AKT1 may be a molecular marker of susceptibility to ferroptosis.

1Papers
ApoptosisCell Line, TumorDrug Resistance, NeoplasmFerroptosisOvarian Neoplasms
Links & IDs
0000-0002-6918-7067
Ovarian Cancer Research Alliance

A global leader in the fight against gynecologic cancer

LIVING LAB
Join the Living LabOur TeamGovernance & EthicsDownloadable Resources
DISCOVERY LAB
Discovery LabHow It WorksUpcoming WebinarsContribute Data
ABOUT
About OCRAGet InvolvedMake a DonationContact Us

© 2025 Ovarian Cancer Research Alliance, Inc.

PrivacyTermsAccessibility